Form 4: CFO Matthew McDonnell Granted 78,740 Anteris RSUs

Anteris Technologies Global Corp.'s Chief Financial Officer, Matthew McDonnell, was granted 78,740 Restricted Stock Units.

Summary

• Matthew McDonnell, Chief Financial Officer of Anteris Technologies Global Corp. (AVR), was granted 78,740 Restricted Stock Units (RSUs) on March 4, 2026.
• Each RSU represents a right to receive one CHESS Depositary Interest (CDI), which in turn represents an interest in one share of the Issuer's common stock.
• The RSUs will vest in three approximately equal annual installments on March 4, 2027, March 4, 2028, and March 4, 2029.
• Vesting is contingent upon Mr. McDonnell's continued service through each respective vesting date.
• Following this transaction, Mr. McDonnell beneficially owns 78,740 derivative securities (RSUs).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it aligns the CFO's long-term interests with shareholder value through equity ownership and promotes executive retention.

Positives

• The grant of 78,740 Restricted Stock Units to the Chief Financial Officer aligns management's interests with long-term shareholder value.
• The three-year vesting schedule encourages the retention of key executive talent within the company.

Negatives

• There is no immediate cash inflow for the CFO as these are RSUs with a future vesting schedule.

Risks

• Vesting of the Restricted Stock Units is subject to the CFO's continued service, meaning unvested units could be forfeited if employment ceases.
• The ultimate value of the RSUs upon vesting is dependent on the future market price of Anteris Technologies Global Corp. common stock.

Future Outlook

The grant of performance-based equity suggests a long-term commitment to the company's future performance and executive retention.

Industry Context

StockSavvy.ai notes that equity grants, particularly Restricted Stock Units with vesting schedules, are a standard practice in executive compensation across the biotechnology and medical device industries. This practice aims to align executive incentives with long-term shareholder value creation and retention, similar to grants seen at companies like Edwards Lifesciences or Medtronic.

Comparison to Industry Standards

• The grant of Restricted Stock Units to a CFO is a common compensation tool, comparable to practices at peer companies in the medical technology sector.
• The three-year vesting schedule is typical for executive equity awards, promoting long-term commitment, similar to vesting schedules observed at companies such as Boston Scientific or Abbott Laboratories for their executive compensation plans.

Stakeholder Impact

• Shareholders: Potential positive impact through better alignment of executive incentives with long-term company performance.
• Employees: May signal stability in executive leadership.

Next Steps

• Continued service by Matthew McDonnell through March 4, 2027, for the first RSU vesting.
• Continued service by Matthew McDonnell through March 4, 2028, for the second RSU vesting.
• Continued service by Matthew McDonnell through March 4, 2029, for the third RSU vesting.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive, which is a standard practice for executive compensation and retention. While it aligns management's interests with shareholders, it does not present new information that would fundamentally alter the investment thesis for Anteris Technologies Global Corp. Therefore, a "hold" recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Anteris Technologies Global Corp, AVR, Matthew McDonnell, CFO, Restricted Stock Units, RSU, Equity Grant, Executive Compensation, SEC Form 4, Insider Transaction, CHESS Depositary Interest, CDI